You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科(01541.HK)IMM2510/AXN-2510獲美FDA批準IND申請
宜明昂科-B(01541.HK)公佈,Instil已自美國食品藥品監督管理局(FDA)取得IMM2510/AXN-2510的新藥臨牀試驗(IND)批準。Instil預計在2025年底前啓動IMM2510/AXN-2510作爲單藥治療複發性/難治性實體腫瘤患者的1b/2期試驗。 2024年8月,公司與Instil(TIL.US)全資附屬Axion Bio立授權及合作協議,授予Axion Bio大中華地區以外研究、開發及商業化若幹靶向程序性細胞死亡配體1及血管內皮生長因子的雙特異性抗體以及若幹靶向細胞毒性T淋巴細胞相關蛋白4的單克隆抗體的獨家授權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account